Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?

Simone Ferrero, Valerio Gaetano Vellone, Fabio Barra, Carolina Scala

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background/aims: Ulipristal acetate ([UPA], Esmya®) is an orally active selective progesterone-receptor modulator that has been approved as preoperative treatment for uterine myomas. This systematic review aims to summarize the available data on surgical outcomes of patients undergoing myomectomy by hysteroscopy or by laparoscopy after preoperative treatment with UPA. Methods: this review was performed following PRISMA guidelines and was registered in PROSPERO (CRD42018092201). PubMed, EMBASE, and Medline databases were systematically searched electronically until March 2018 for keywords concerning this topic. There were included only peer-reviewed, English language journal articles. Results: two prospective studies and 4 retrospective studies were included. The effect of UPA on the endometrium does not increase the technical difficulty during hysteroscopic myomectomy, but it increases the chance of complete primary resection in complex hysteroscopic myomectomies. Moreover, UPA does not increase the overall technical difficulty of laparoscopic myomectomy. Contradictory results have been reported on the impact of UPA on the separation of the myoma from the myometrium and on the consistency of the myomas. Conclusion: current results support the use of UPA prior to both surgical procedures. Further studies should confirm these preliminary findings and to assess the long-term outcomes of myomectomies following UPA treatment.

Original languageEnglish
Pages (from-to)313-325
Number of pages13
JournalGynecologic and Obstetric Investigation
Volume84
Issue number4
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Hysteroscopy
Myoma
Uterine Myomectomy
Laparoscopy
ulipristal acetate
Myometrium
Progesterone Receptors
Endometrium
PubMed
Language
Therapeutics
Retrospective Studies
Databases
Prospective Studies
Guidelines

Keywords

  • Hysteroscopy
  • Laparoscopy
  • Myoma
  • Myomectomy
  • Ulipristal acetate

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas : Help or Hindrance? / Ferrero, Simone; Vellone, Valerio Gaetano; Barra, Fabio; Scala, Carolina.

In: Gynecologic and Obstetric Investigation, Vol. 84, No. 4, 01.07.2019, p. 313-325.

Research output: Contribution to journalReview article

@article{851c8f04f69a434798dbf3c13d0d0810,
title = "Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?",
abstract = "Background/aims: Ulipristal acetate ([UPA], Esmya{\circledR}) is an orally active selective progesterone-receptor modulator that has been approved as preoperative treatment for uterine myomas. This systematic review aims to summarize the available data on surgical outcomes of patients undergoing myomectomy by hysteroscopy or by laparoscopy after preoperative treatment with UPA. Methods: this review was performed following PRISMA guidelines and was registered in PROSPERO (CRD42018092201). PubMed, EMBASE, and Medline databases were systematically searched electronically until March 2018 for keywords concerning this topic. There were included only peer-reviewed, English language journal articles. Results: two prospective studies and 4 retrospective studies were included. The effect of UPA on the endometrium does not increase the technical difficulty during hysteroscopic myomectomy, but it increases the chance of complete primary resection in complex hysteroscopic myomectomies. Moreover, UPA does not increase the overall technical difficulty of laparoscopic myomectomy. Contradictory results have been reported on the impact of UPA on the separation of the myoma from the myometrium and on the consistency of the myomas. Conclusion: current results support the use of UPA prior to both surgical procedures. Further studies should confirm these preliminary findings and to assess the long-term outcomes of myomectomies following UPA treatment.",
keywords = "Hysteroscopy, Laparoscopy, Myoma, Myomectomy, Ulipristal acetate",
author = "Simone Ferrero and Vellone, {Valerio Gaetano} and Fabio Barra and Carolina Scala",
year = "2019",
month = "7",
day = "1",
doi = "10.1159/000495347",
language = "English",
volume = "84",
pages = "313--325",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas

T2 - Help or Hindrance?

AU - Ferrero, Simone

AU - Vellone, Valerio Gaetano

AU - Barra, Fabio

AU - Scala, Carolina

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background/aims: Ulipristal acetate ([UPA], Esmya®) is an orally active selective progesterone-receptor modulator that has been approved as preoperative treatment for uterine myomas. This systematic review aims to summarize the available data on surgical outcomes of patients undergoing myomectomy by hysteroscopy or by laparoscopy after preoperative treatment with UPA. Methods: this review was performed following PRISMA guidelines and was registered in PROSPERO (CRD42018092201). PubMed, EMBASE, and Medline databases were systematically searched electronically until March 2018 for keywords concerning this topic. There were included only peer-reviewed, English language journal articles. Results: two prospective studies and 4 retrospective studies were included. The effect of UPA on the endometrium does not increase the technical difficulty during hysteroscopic myomectomy, but it increases the chance of complete primary resection in complex hysteroscopic myomectomies. Moreover, UPA does not increase the overall technical difficulty of laparoscopic myomectomy. Contradictory results have been reported on the impact of UPA on the separation of the myoma from the myometrium and on the consistency of the myomas. Conclusion: current results support the use of UPA prior to both surgical procedures. Further studies should confirm these preliminary findings and to assess the long-term outcomes of myomectomies following UPA treatment.

AB - Background/aims: Ulipristal acetate ([UPA], Esmya®) is an orally active selective progesterone-receptor modulator that has been approved as preoperative treatment for uterine myomas. This systematic review aims to summarize the available data on surgical outcomes of patients undergoing myomectomy by hysteroscopy or by laparoscopy after preoperative treatment with UPA. Methods: this review was performed following PRISMA guidelines and was registered in PROSPERO (CRD42018092201). PubMed, EMBASE, and Medline databases were systematically searched electronically until March 2018 for keywords concerning this topic. There were included only peer-reviewed, English language journal articles. Results: two prospective studies and 4 retrospective studies were included. The effect of UPA on the endometrium does not increase the technical difficulty during hysteroscopic myomectomy, but it increases the chance of complete primary resection in complex hysteroscopic myomectomies. Moreover, UPA does not increase the overall technical difficulty of laparoscopic myomectomy. Contradictory results have been reported on the impact of UPA on the separation of the myoma from the myometrium and on the consistency of the myomas. Conclusion: current results support the use of UPA prior to both surgical procedures. Further studies should confirm these preliminary findings and to assess the long-term outcomes of myomectomies following UPA treatment.

KW - Hysteroscopy

KW - Laparoscopy

KW - Myoma

KW - Myomectomy

KW - Ulipristal acetate

UR - http://www.scopus.com/inward/record.url?scp=85058799764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058799764&partnerID=8YFLogxK

U2 - 10.1159/000495347

DO - 10.1159/000495347

M3 - Review article

C2 - 30554215

AN - SCOPUS:85058799764

VL - 84

SP - 313

EP - 325

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 4

ER -